Inizio Ignite

Merck and Tridonic Enter Into License Agreement for White LEDs

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...
- Advertisement -

Merck, a leading company for innovative and top-quality high-tech products in the healthcare, life science and performance materials sectors, announced today that it has entered into a license agreement with Tridonic Jennersdorf GmbH (Tridonic) covering silicate phosphors for use in white light LEDs.

Along with Toyoda Gosei Co. Ltd. (Japan), Leuchtstoffwerk Breitungen GmbH (Germany), and Litec GbR (Germany), Tridonic holds basic patents relating to a technology to generate white light using blue LEDs and novel yellow silicate phosphors. This combination of silicate phosphors applied to blue LED chips enable manufacturing of packaged white LEDs with high accuracy and high brightness. Primary applications include backlights for cell phones, laptops, GPS and other small displays, which account for a high share of today’s global LED market.

Latest stories

Related stories

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »